Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength? [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
This compares to the stock's 6.9% loss over the past four weeks. The surge is mostly attributable to positive results from the late study PURPOSE 1 wherein twice-yearly lenacapavir demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. On the basis of these results, the independent Data Monitoring Committee recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants. This HIV and hepatitis C drugmaker is expected to post quarterly earnings of $1.58 per share in its upcoming report, which represents a year-over-year change of +17.9%. Revenues are expected to be $6.66 billion, up 0.9% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Gilead, the consensus
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- NEW DATA SUPPORT THE USE OF BICTEGRAVIR TABLET REGIMEN TO TREAT PEOPLE WITH HIV AND INDIVIDUALS WITH HIV/HBV-COINFECTION IN ASIA [Yahoo! Finance]Yahoo! Finance
- Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing 4.6% over the past year [Yahoo! Finance]Yahoo! Finance
- Global Autologous Stem Cell & Non-Stem Cell Therapies Market: $5.5B in 2024 to $22.2B by 2029, CAGR 32.3% | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- GILEAD'S TWICE-YEARLY LENACAPAVIR DEMONSTRATED 100% EFFICACY AND SUPERIORITY TO DAILY TRUVADA® FOR HIV PREVENTION [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- GILD's page on the SEC website